Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer

Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway

(2015) Xiao-Li Zhang et al.   Anti-Cancer Agents in Medicinal Chemistry

The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil

(2015) Marzia B. Gariboldi et al.   CANCER LETTERS

HIF1α Expression under Normoxia in Prostate Cancer— Which Pathways to Target?

(2015) Weranja K.B. Ranasinghe et al.   JOURNAL OF UROLOGY

Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

(2015) Carina Fischer et al.   Molecular Cancer

Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals

(2015) Jie Luo et al.   Oncotarget

IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules

(2015) Shanzhou Duan et al.   Oncotarget

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

(2015) Zachary C. Dobbin et al.   Oncotarget

Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells

(2014) Debangshu Samanta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systems biology of cisplatin resistance: past, present and future

(2014) L Galluzzi et al.   Cell Death & Disease

Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles

(2013) Johanna Myllyharju et al.   BIOLOGICAL CHEMISTRY

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

(2013) Woondong Jeong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High-density lipoproteins augment hypoxia-induced angiogenesis via regulation of post-translational modulation of hypoxia-inducible factor 1α

(2013) Joanne T. M. Tan et al.   FASEB JOURNAL

CD133+ cancer stem cells in lung cancer 

(2013) Zhen Xu   Frontiers in Bioscience-Landmark

Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature

(2013) Martin P. Barr et al.   PLoS One

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition

(2012) Sreenivasulu Chintala et al.   BMC CANCER

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

(2012) J. Moroney et al.   CLINICAL CANCER RESEARCH

Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy

(2012) Chin Hao Chang et al.   INTERNATIONAL JOURNAL OF CANCER

Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL

(2012) Marco A. Hernandez-Luna et al.   LEUKEMIA & LYMPHOMA

A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

(2011) Kyeong Lee et al.   ARCHIVES OF PHARMACAL RESEARCH

Interleukin-6 plays an essential role in hypoxia-inducible factor 2α-induced experimental osteoarthritic cartilage destruction in mice

(2011) Je-Hwang Ryu et al.   ARTHRITIS AND RHEUMATISM

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines

(2011) Lu Cao et al.   BMC GASTROENTEROLOGY

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1  in Advanced Solid Tumors

(2011) S. Kummar et al.   CLINICAL CANCER RESEARCH

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Hypoxia Increases the Expression of Stem-Cell Markers and Promotes Clonogenicity in Glioblastoma Neurospheres

(2010) Eli E. Bar et al.   AMERICAN JOURNAL OF PATHOLOGY

Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling

(2010) J. P. Sullivan et al.   CANCER RESEARCH

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

(2010) Alex Chang   LUNG CANCER

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

(2009) G. Bertolini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells

(2008) Yu-Chih Chen et al.   PLoS One